Literature DB >> 34421206

Evaluation of Clinical Outcomes With the V-Go Wearable Insulin Delivery Device in Patients With Type 2 Diabetes.

Lisa T Meade1,2, Dawn Battise1,3.   

Abstract

Uncontrolled type 2 diabetes can lead to a multitude of health complications. Insulin therapy is recommended when patients are unable to reach their A1C goal with oral or noninsulin injectable diabetes medications. This study evaluated the clinical benefits of switching from multiple daily insulin injections to a wearable insulin delivery device (V-Go). A retrospective chart review was conducted on 44 patients who received prescriptions for the V-Go at two family medicine offices. Investigators found a significant reduction in A1C and daily insulin requirements with no impact on weight or BMI.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID： 34421206      PMCID： PMC8329021          DOI： 10.2337/cd20-0094

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


  30 in total

1.  The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus.

Authors:  Jaime A Davidson
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

2.  V-Go Insulin Delivery System Versus Multiple Daily Insulin Injections for Patients With Uncontrolled Type 2 Diabetes Mellitus.

Authors:  Abigail Winter; Michaela Lintner; Emily Knezevich
Journal:  J Diabetes Sci Technol       Date:  2015-04-21

Review 3.  Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes.

Authors:  Stuart A Ross
Journal:  Am J Med       Date:  2013-09       Impact factor: 4.965

4.  TheV-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control.

Authors:  Cheryl R Rosenfeld; Nancy J Bohannon; Bruce Bode; Adam S Kelman; Shari N Mintz; Alan B Schorr; Marc I Sandberg; Sridhar Nambi; Sumon K Agarwala; Steven B Leichter; Bart Larrabee; Lei Shi; Poul Strange
Journal:  Endocr Pract       Date:  2012 Sep-Oct       Impact factor: 3.443

5.  Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.

Authors:  Yves Reznik; Ohad Cohen; Ronnie Aronson; Ignacio Conget; Sarah Runzis; Javier Castaneda; Scott W Lee
Journal:  Lancet       Date:  2014-07-02       Impact factor: 79.321

6.  Measuring psychological insulin resistance: barriers to insulin use.

Authors:  Mary E Larkin; Virginia A Capasso; Chien-Lin Chen; Ellen K Mahoney; Barbara Hazard; Enrico Cagliero; David M Nathan
Journal:  Diabetes Educ       Date:  2008 May-Jun       Impact factor: 2.140

Review 7.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

Review 8.  7. Diabetes Technology: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

9.  Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.

Authors:  Amit D Raval; Matthew H Nguyen; Siting Zhou; Michael Grabner; John Barron; Ralph Quimbo
Journal:  J Manag Care Spec Pharm       Date:  2019-10

10.  The Clinical and Economic Impact of the V-Go® Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk.

Authors:  Rosemarie Lajara; Carla Nikkel; Scott Abbott
Journal:  Drugs Real World Outcomes       Date:  2016-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.